RecruitingPhase 2NCT06835322

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Effect of Finerenone on Proteinuria and GFR Progression in Patients With Non Diabetic Glomerulonephritis: A Randomized Clinical Trial

Sponsor

Alexandria University

Enrollment

100 participants

Start Date

Feb 20, 2025

Study Type

INTERVENTIONAL

Conditions

Glomerulonephritis

Summary

This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

GN patients on maximum tolerated doses of an ACEi or ARBs together with their immunosuppression protocol (if needed) for at least 4 weeks.
urinary protein excretion >500 mg/g.
Adult patients with age above 18 years.
eGFR ≥ 25 mL/ min/1.73 m2.
baseline serum potassium level <5 mEq/L.

Exclusion Criteria6

Patients with diabetes mellitus (type 1 or 2).
Other non-glomerular kidney diseases.
Heart failure.
Breast feeding or pregnancy.
Patients who received medications to treat hyperkalemia 4 weeks before study.
Uncontrolled hypertension (BP > 160/100).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFinerenone

50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.

DRUGPlacebo

50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.